Early serum (1→3)‐β‐D‐glucan levels in patients with burn injury
暂无分享,去创建一个
J. Jeng | A. Jaskille | M. Finkelman | T. Walsh | J. Shupp | S. Shoham | M. Jordan | R. Petraitiene | Sarah E. Matt | Melissa A. Kath | A. Pavlovich | D. T. Nguyen | Melissa A. Kath | R. Petraitienė | Amin D. Jaskille | Do T. Nguyen
[1] K. Colpaert,et al. Morbidity and mortality of bloodstream infections in patients with severe burn injury. , 2010, American journal of critical care : an official publication, American Association of Critical-Care Nurses.
[2] J. Wasiak,et al. Candida in Burns: Risk Factors and Outcomes , 2010, Journal of burn care & research : official publication of the American Burn Association.
[3] B. Alexander,et al. Quantification of 1,3-β-d-Glucan Levels in Children: Preliminary Data for Diagnostic Use of the β-Glucan Assay in a Pediatric Setting , 2007, Clinical and Vaccine Immunology.
[4] B. Alexander,et al. Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. , 2007, Clinical and vaccine immunology : CVI.
[5] B. Alexander,et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] L. Magnotti,et al. Burns, bacterial translocation, gut barrier function, and failure. , 2005, The Journal of burn care & rehabilitation.
[7] J. W. Pickering,et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. , 2005, Journal of clinical microbiology.
[8] E. Estey,et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome , 2004 .
[9] E. Estey,et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] J. Kalbfleisch,et al. Serum Glucan Levels Are Not Specific for Presence of Fungal Infections in Intensive Care Unit Patients , 2003, Clinical Diagnostic Laboratory Immunology.
[11] M. Usami,et al. Positive (1→3)‐β‐d‐glucan in blood components and release of (1→3)‐β‐d‐glucan from depth‐type membrane filters for blood processing , 2002 .
[12] B. Wong,et al. Current Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections , 2002, Clinical Microbiology Reviews.
[13] M. Usami,et al. Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing. , 2002, Transfusion.
[14] A. Hishida,et al. Elevation of Blood (1→3)-Beta-D-Glucan Concentrations in Hemodialysis Patients , 2001, Nephron.
[15] Daniel Poulain,et al. New Enzyme Immunoassays for Sensitive Detection of CirculatingCandida albicans Mannan and Antimannan Antibodies: Useful Combined Test for Diagnosis of Systemic Candidiasis , 1999, Journal of Clinical Microbiology.
[16] A. Nakao,et al. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. , 1997, Hepato-gastroenterology.
[17] B. Pruitt,et al. Incidence of bacteremia after burn wound manipulation in the early postburn period. , 1997, The Journal of trauma.
[18] J. Wingard,et al. Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol. , 1995, The American journal of medicine.
[19] S. Kohno,et al. Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes , 1995, The Lancet.